ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy

被引：0
|
作者：
Evans, T. R. Jeffry
Kudo, Masatoshi
Cheng, Ann-Lii
Wyrwicz, Lucjan S.
Ngan, Roger Kc
Blanc, Jean-Frederic
Baron, Ari David
Vogel, Arndt
Ikeda, Masafumi
Piscaglia, Fabio
Qin, Shukui
Hoshi, Taisuke
Tamaki, Ryuji
Funahashi, Yasuhiro
Okpara, Chinyere E.
Sagane, Koji
Xing, Dongyuan
Minoshima, Yukinori
Finn, Richard S.
机构：
[1] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2] Kindai Univ, Fac Med, Osaka, Japan
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan
[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[6] Univ Hong Kong, Hong Kong, Peoples R China
[7] Univ Bordeaux, Bordeaux, France
[8] Sutter Calif Pacif Med Ctr, San Francisco, CA USA
[9] Hannover Med Sch, Hannover, Germany
[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[11] Univ Bologna, IRCCS Azienda Osped, Bologna, Italy
[12] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China
[13] Eisai & Co Ltd, Ibaraki, Japan
[14] Eisai Ltd, Hatfield, Herts, England
[15] Eisai Inc, Nutley, NJ USA
[16] UCLA Med Ctr, Geffen Sch Med, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4094
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC)
    Peck-Radosavljevic, Markus
    Goyal, Lipika
    Strasser, Simone
    Matilla Pena, Ana Maria
    Marinho, Rui
    Granito, Alessandro
    Roderburg, Christoph
    Marsico, Mark
    Christou, Vanessa C.
    Xie, Ran
    Saraf, Pankhoori
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [32] Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Shen, Lin
    Guo, Ye
    Zhang, Yanqiao
    Li, Wei
    Gong, Jifang
    Li, Qun
    Ma, Zhigang
    Wang, Nanya
    Su, Rila
    Cai, Zhongheng
    Guo, Rong
    Li, Peiqi
    Tse, Archie N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16191 - E16191
  • [33] Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN).
    Huynh, Jasmine
    Cho, May Thet
    Kim, Edward Jae-Hoon
    Ren Min
    Robbins, Carol
    Amaya-Chanaga, Carlos
    Vogel, Arndt
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [34] Phase II study of transhepatic artery chemoembolization (TACE) combined with tislelizumab (TIS) and lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma(uHCC)
    Nong, X.
    Xie, J-L.
    Zhang, Y-M.
    Liang, J-C.
    Pan, Z-L.
    Zhang, Z-M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S871 - S871
  • [35] Unresectable hepatocellular carcinoma treated with lenvatinib or sorafenib: A disease modeling study.
    Tremblay, Gabriel
    Copher, Ronda
    Garib, Shan Ashton
    Pan, Janice
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] The comparative efficacy of atezolizumab and bevacizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC).
    Trueman, David
    Liu, Yifeng
    Lucero, Melanie
    Meier, Genevieve
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).
    Lim, Chloe
    Amaro, Carla Pires
    Ding, Philip Q.
    Cheung, Winson Y.
    Tam, Vincent C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 553 - 553
  • [38] Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight (bw) >80 kg in REFLECT
    Vogel, A.
    Kudo, M.
    Cheng, A. -L.
    Sung, M. W.
    Finn, R. S.
    Lin, A. Y.
    Abou-Alfa, G. K.
    Alsina, A.
    Breder, V.
    Tebbutt, N.
    Osterlund, P.
    Yen, C. J.
    Ren, M.
    Misir, S.
    Dutcus, C. E.
    Palmer, D.
    Merle, P.
    Pinter, M.
    Evans, T. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 242 - 243
  • [39] PATIENT EDUCATION AND MANAGEMENT OF ADVERSE REACTIONS IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) TREATED WITH LENVATINIB: NURSE PRACTITIONERS' PERSPECTIVE
    Jones, Anna
    Moore, Ann
    Robbins, Carol
    Amaya-Chanaga, Carlos
    Sung, Max W.
    Baron, Ari D.
    ONCOLOGY NURSING FORUM, 2021, 48 (02)
  • [40] Comparing first-line (1L) atezolizumab plus bevacizumab (A plus B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database.
    Kaplan, David Edward
    Tan, Amie
    Xiang, Cheryl
    Mu, Fan
    Ogale, Sarika
    Hernandez, Sairy
    Li, Jiayang
    Lin, Yilu
    Shi, Lizheng
    Singal, Amit G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 446 - 446
12345